Skip to content

ELANVeterinary medicines

Elanco Animal Health

By

Updated

Not investment advice. Kevin may own this stock. How we value stocks

History
Price
$25.77
Discount category
Close to intrinsic value
Analysts
Bullish
Next earnings
Feb 23 · · estimated
Pick status
Research only

In short

Thesis
The market weighs the new pet products of Elanco against its debt and strong competitors, and steady share gains with lower debt through 2027 can lift its value.
Gap
Can close. The Q4 2026 report and 2027 guidance, expected in late February 2027, and the EU launch of Credelio Quattro in Q1 2027 show whether new products keep growth and margins up.

Company guidance: 2026 revenue $5.155 to $5.18 billion; adjusted EBITDA $1.05 to $1.065 billion; adjusted EPS $1.17 to $1.20 (, Q3 2026 results release (8-K))

Price history

About

Elanco Animal Health Incorporated (Elanco) is based in Indianapolis, Indiana. It develops, makes and sells medicines, vaccines and other products for pets and farm animals. Its Pet Health brands include Zenrelia, Credelio Quattro, Advantage and Seresto.

Its Farm Animal products serve cattle, poultry and swine. Revenue was $1,265 million in Q3 2026: Pet Health $608 million, Farm Animal $631 million and contract manufacturing and other $26 million. In April 2026 it bought AHV International, a Dutch farm animal health company.

Elanco pays no dividend. The common stock trades on the NYSE in US dollars. Elanco files 10-K and 10-Q reports.

Thesis

The price of Elanco depends on whether its new pet products keep growth and margins up while the company pays down the debt from earlier purchases. Revenue grew 9% in Q3 2026 on an organic constant currency basis, with price up 4%, and the adjusted gross margin rose 300 basis points to 56.1%. Zenrelia and Credelio Quattro gained share in the US, and Credelio Quattro became its largest US Pet Health brand.

The net leverage ratio fell to 2.9 times adjusted EBITDA at September 30, 2026, from 3.6 times at the end of 2025. For the price to hold or rise, three things must be true. Zenrelia, Credelio Quattro and the new product Befrena must keep gaining share against strong competitors.

Elanco must reach its 2026 guidance of adjusted EBITDA of $1,050 million to $1,065 million and then its 2027 outlook of high-single-digit adjusted EBITDA growth and low-double-digit adjusted EPS growth. Free cash flow must keep reducing the debt, so that interest costs fall. The Q4 2026 report, expected in late February 2027, with 2027 guidance, and the EU launch of Credelio Quattro in Q1 2027 are the next tests.

Checkpoints

  1. Feb 23, 2027 · est.Pending
    Q4 2026 results and 2027 guidance2026 adjusted EBITDA is in the guided range of $1,050 million to $1,065 million and 2027 guidance keeps high-single-digit adjusted EBITDA growth, and this passes; a result below the range or lower 2027 growth fails.
  2. Q1 2027 · est.Pending
    EU launch of Credelio QuattroElanco launches Credelio Quattro in the EU in Q1 2027, as it expects, and this passes; a delay past Q2 2027 fails.

Every passed and failed checkpoint across all picks

Recent events

  • November 6, 2026Elanco reported Q3 2026 results. Revenue rose 11% to $1,265 million, or 9% on an organic constant currency basis, adjusted EBITDA rose 23% to $243 million and adjusted EPS was $0.27. It raised 2026 guidance to revenue of $5,155 million to $5,180 million, adjusted EBITDA of $1,050 million to $1,065 million and adjusted EPS of $1.17 to $1.20.
  • November 6, 2026Elanco said that Credelio Quattro received a positive opinion from the European Medicines Agency, and it expects to launch the product in the EU in Q1 2027. It also said that Befrena moves into full launch in Q1 2027.
  • November 3, 2026Jamie Preston became Executive Vice President and Chief People Officer. Dave Kinard, who held the role, plans to retire at the end of 2026.
Show 2 older events
  • April 30, 2026Elanco completed the purchase of AHV International, a Dutch farm animal health company that works to reduce the need for antibiotics, for an estimated total price of $241 million.
  • December 5, 2025The board approved a restructuring plan that cuts about 300 jobs and moves about 300 more to growth areas or lower-cost places, with pretax charges of about $175 million.

Latest news and filings

Last earnings
November 6, 2026 (8-K on sec.gov)
Next earnings
Expected about February 23, 2027. The company has not confirmed the date.

Every filing on SEC EDGAR (CIK 1739104)

Risks

  • Debt is high. Debt principal was $3,470 million at September 30, 2026, and net interest expense was $59 million in Q3 2026. Lower earnings would slow the payback of debt.
  • Pet Health products face strong competitors, also in the markets of Zenrelia and Credelio Quattro, and from generic products. Lost share would slow growth.
  • Elanco faces lawsuits. A securities class action says that Elanco made false or misleading statements about the safety and label of Zenrelia, and other lawsuits allege unlawful sales practices for flea and tick products.
  • Farm animal sales depend on disease and farm economics. Poultry revenue fell 7% in Q3 2026, and an outbreak of disease could cut demand.
  • Changes in tariffs, trade rules and exchange rates can change costs and reported revenue.

Key statistics

Market cap
$13B
Shares of Nov 4, 2026
EPS (trailing)
-$0.30
12 months to Sep 30, 2026
52-week range
$19.40 – $27.98
To Nov 12, 2026
Beta
1.73
Vs S&P 500, 5 years monthly, to Oct 30, 2026
Average volume
5.3M
3 months, to Nov 12, 2026

Balance sheet

Cash
$465M
Debt
$3.5B
Net debt
$3.0B
Net debt / EBITDA
2.9×
EBITDA $1.1B, last 12 months
Credit line
$750M
undrawn, to July 2029

Cash against debt

Cash$465M
Debt$3.5B

debt covered by cashnet debt $3.0B

Leverage: net debt / EBITDA

low, under 2×medium, 2× to 4×high, over 4×

When the debt is due

12 months$74M
Later$3.4B

The last debt is due in 2032.

At September 30, 2026, Elanco had debt principal of $3,470 million: term loans of $2,620 million, Senior Notes due 2028 of $750 million at 6.40% and $100 million under its securitization facility. Finance lease liabilities were $258 million.

Dividends

Elanco Animal Health does not pay a dividend.

Source: company filings and market data, read on November 12, 2026.

Questions about Elanco Animal Health

What does Elanco Animal Health do?

Elanco Animal Health Incorporated (Elanco) is based in Indianapolis, Indiana. It develops, makes and sells medicines, vaccines and other products for pets and farm animals. Its market cap is $13B at the current price of $25.77.

When does Elanco Animal Health report earnings next?

This is an estimate: Elanco Animal Health may report on February 23, 2027. It last reported results on November 6, 2026.

Is Elanco Animal Health stock below its intrinsic value?

Elanco Animal Health stock is close to intrinsic value. This is general information, not advice.

What changed recently at Elanco Animal Health?

The latest update is from November 6, 2026. Elanco reported Q3 2026 results.

What are the main risks for Elanco Animal Health?

Debt is high. Pet Health products face strong competitors, also in the markets of Zenrelia and Credelio Quattro, and from generic products. Elanco faces lawsuits.

How much debt and cash does Elanco Animal Health have?

At September 30, 2026, Elanco Animal Health had $3.5B of debt and $465M of cash.

Does Elanco Animal Health pay a dividend?

No. Elanco Animal Health does not pay a dividend.

Valuation against peers

CompanyP/E, last 4 quartersEV/EBITDA, last yearFree cash flow yield, last year10-year average P/E
ELANElanco Animal Healthn/an/a2.2%n/a
JAZZJazz Pharmaceuticals68.1xn/a8.8%20.0x
BBIOBridgeBio Pharman/an/a-3.0%n/a
PCGPG&E10.2xn/a-8.3%17.0x
BABoeing16.1x23.8x-1.5%n/a
Peer median16.1xn/a-2.3%n/a
  • Its free cash flow yield is 2.2%, 4.5 points above the peer median of -2.3%.

The peers are the companies on this site most like ELAN. The multiples come from company filings and today's price. There are no analyst forecasts: they all look back. EV/EBITDA is left out for banks, insurers and real estate companies. This is general information, not advice.

Similar companies

  • GMABGenmabShares: High debt, Regulation and courts
    Intrinsic value
    Far above intrinsic value (AI estimate)
    Gap
    Slow
  • JAZZJazz PharmaceuticalsShares: Regulation and courts, High debt
    Intrinsic value
    Close to intrinsic value
    Gap
    Can close
  • BBIOBridgeBio PharmaShares: Regulation and courts, High debt
    Intrinsic value
    Close to intrinsic value
    Gap
    Can close
  • PCGPG&EShares: Regulation and courts, High debt
    Intrinsic value
    Far below intrinsic value
    Gap
    Will probably not close
  • HONAHoneywell AerospaceShares: High debt, Regulation and courts
    Intrinsic value
    Deep below intrinsic value
    Gap
    Can close

Loading your notes…

Read it all? Star ELAN or pass, then go on to the next one.